An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...

The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...

Spravato is now the first-ever stand-alone therapy for treatment-resistant depression, and is on its way to becoming a ...

Here's what MDs want you to know about Spravato, the latest FDA-approved standalone nasal spray for depression.

We have made great strides in the medical community, with people having access to life-saving physical drugs as well as ...

Johnson & Johnson's ketamine-derived nasal spray has been approved as a standalone treatment to fight depression for those ...

Effective treatments for people with serious depression who have not been helped by antidepressant medications have novel ...

Blue Monday originated from a publicity stunt, but seasonal affective disorder is a real affliction that affects millions of ...

JNJ stock reporting earnings, expecting $2 EPS and $22.44B revenue, approval for Spravato, mixed chart signals, $167.71 price ...

CHARLOTTESVILLE, Va. (WVIR) - According to one UVA health expert, antidepressants, and medication prescribed to help people ...

After getting a metastatic breast cancer diagnosis, you may experience anxiety and depression. Here are some ways to manage ...

With the new year here and winter weather upon us, many people are dealing with seasonal depression.Studies show that ...